Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 ActivationPatricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, et al.
The Lancet. Oncology|May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Breast Cancer Research and Treatment|August 8, 2019
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastasesZhe-Bin Liu, Nader E Ezzedine, Agda K Eterovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2021
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast CancerCristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, et al.
The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
Cancers|May 6, 2020
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast CancerPaula González-Alonso, Sandra Zazo, Ester Martín-Aparicio, et al.
Cell Death and Differentiation|March 10, 2023
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cellsSara S Oltra, Sara Colomo, Laura Sin, et al.
NPJ Breast Cancer|September 11, 2021
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expressionJaume Fores-Martos, Raimundo Cervera-Vidal, Julia Sierra-Roca, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 ActivationPatricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, et al.
The Lancet. Oncology|May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Breast Cancer Research and Treatment|August 8, 2019
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastasesZhe-Bin Liu, Nader E Ezzedine, Agda K Eterovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2021
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast CancerCristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, et al.
The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
Cancers|May 6, 2020
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast CancerPaula González-Alonso, Sandra Zazo, Ester Martín-Aparicio, et al.
Cell Death and Differentiation|March 10, 2023
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cellsSara S Oltra, Sara Colomo, Laura Sin, et al.
NPJ Breast Cancer|September 11, 2021
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expressionJaume Fores-Martos, Raimundo Cervera-Vidal, Julia Sierra-Roca, et al.
Pageof 19